October 9, 2024 11:37 AM EDT
News Briefing

Cri­net­ics’ $500M of­fer­ing; Boehringer inks deal with macro­cy­cles biotech

ENDPOINTS

Plus, news about In­hibikase, Bio-Thera, Richter, In­no­Care and Schol­ar Rock:

Cri­net­ics prices $500M of­fer­ing: The San Diego biotech up­sized the of­fer­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

‘Just the be­gin­ning’: No­bel Prizes show the AI era has ar­rived in biotech

David Bak­er, Demis Has­s­abis and John Jumper win chem­istry No­bel for com­pu­ta­tion­al pro­tein pre­dic­tion and de­sign

AI biotech in­sitro part­ners with Lil­ly on meta­bol­ic dis­ease drugs

Pure­spring nabs $105M to take gene ther­a­py in­to the clin­ic as IgAN field ma­tures

Kevin Tang's Con­cen­tra swoops in on an­oth­er strug­gling biotech, of­fer­ing to buy Kezar

Zealand Phar­ma hit with sec­ond CRL for glucagon re­cep­tor ag­o­nist

A service from the Financial Times